| Gene symbol | CD19 | Synonyms | B4, CVID3 | Type of gene | protein-coding |
| Chromosome | 16 | Map location | 16p11.2 | dbXrefs | |
| Description | CD19 molecule | ||||
| GTO ID | GTC3866 |
| Trial ID | NCT06384976 |
| Disease | Multiple Sclerosis |
| Altered gene | CD19 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | KYV-101 |
| Phase | Phase2 |
| Recruitment status | Not Recruiting |
| Title | A Phase 2, Open-Label, Randomized, Multicenter Study of KYV-101, an Autologous Fully Human Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Primary and Secondary Progressive Multiple Sclerosis (KYSA-7) |
| Year | 2024 |
| Country | United States |
| Company sponsor | Kyverna Therapeutics |
| Other ID(s) | KYV101-007 |
| Cohort 1 | |||||||||||
|
|||||||||||